Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and
efficacy of APG-2575 single agent and in combination with other therapeutic agents in
patients with relapsed/refractory CLL/SLL.